• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

California insurance board subpoenas Valeant

November 10, 2016 By Sarah Faulkner

California insurance board subpoenas ValeantValeant Pharmaceuticals (NYSE:VRX) said yesterday that it received an investigative subpoena from the California Dept. of Insurance last month over its ties to a specialty pharmacy, Philidor Rx Services. The company is facing allegations that it used Philidor to force customers to pay higher prices for its drugs.

The subpoena reportedly asked for materials such as documents regarding the Laval, Canada-based company’s relationship with Philidor and other California-based pharmacies, as well as tactics it used to market and distribute its products in California.

Reports surfaced last year that Valeant used Philidor to move past insurer reimbursement rejections of its drugs, as Philidor would resubmit claims to insurers until they were approved. The company said in a regulatory filing that it is cooperating with the investigation.

Valeant’s former CEO and CFO are also undergoing a criminal probe for potential accounting fraud related to Valeant’s ties to Philidor. Since the company’s relationship to Philidor was 1st disclosed last year, Valeant has cut all ties with the pharmacy, appointed new leadership, and conducted an internal review.

The news of the California insurance board’s subpoena comes 1 week after the Wall Street Journal reported that Valeant is exploring a sale of its eye surgery business that could be worth as much as $2.5 billion. While the process is still in early stages and may not even happen, the company is in discussions with 3rd parties for “various divestitures”, according to the newspaper. Valeant said it won’t give up the contact lenses, solutions and eye drugs that it acquired with its $9 billion purchase of Bausch & Lomb in 2013.

Yesterday, the FDA flagged Valeant for 5 violations of good manufacturing practices, corrective & preventive action and more for its small-particle aerosol generator, the SPAG-2 device, and a high-precision compound and dispensing pen, the OralPharma OnSet mixing pen.

Filed Under: Drug-Device Combinations, Featured, Legal News, Respiratory Tagged With: Valeant Pharmaceuticals

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS